Malin Corporation Quick Ratio
Quick Ratio (Acid Test) of Malin Corporation (MLC.IR) as of Sep 25, 2026.
Get this data via API
Financial Data API
Quick Ratio
-
Last updated:
Quick Ratio (Acid Test) of Malin Corporation is 2026 - . Quick Ratio (Acid Test) of Malin Corporation was 2025 - . It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API
Malin Corporation Stock analysis
What does Malin Corporation do? Malin Corporation PLC is an Irish company that was founded in 2014. The company is a subsidiary of Elan, a company specialized in pharmaceutical development.
Malin has focused its business model on identifying, supporting, and scaling startup companies. The company supports and invests in startups in the biopharmaceutical industry that focus on new and innovative therapies. Malin offers help and advice to its portfolio companies in product development and business organization.
The company has invested in various areas of the biopharmaceutical industry. For example, it has supported YumaTherapeutics, a company focused on the discovery and development of novel therapeutics for infectious diseases. Malin has also provided financial support to Seres Therapeutics, which has built a pipeline of therapeutics targeting the microbiome, the collection of microorganisms living in the gut. Malin has invested in Inivata, a company specialized in the development of cancer diagnostics.
Furthermore, Malin has various other companies in its investment pipeline that deal with a variety of therapeutic possibilities. This includes therapies for genetic diseases and inherited metabolic disorders, as well as applications of gene therapy and immunotherapy.
Malin Corporation PLC has also developed its own products and partnerships. One of these partnerships is with Novaerus, another Irish company specialized in the development of air purification systems. Novaerus systems use a plasma-based ion system to destroy bacteria, viruses, and fungi in the air, thus preventing infections.
Malin is also involved in research collaborations. One collaboration is with University College Dublin, where Malin provides financial support for research on biopharmaceutical processes.
The history of Malin Corporation PLC is characterized by a strong commitment to supporting innovative companies in the biopharmaceutical industry. The company aims to promote the growth and development of startups, offering not only financial support but also advice and expertise.
Malin has diversified its investments in various areas of the biopharmaceutical industry and focuses on promoting products that improve people's health and well-being. The company has also developed its own products and partnerships to bring new technologies and therapies to the market.
Overall, Malin Corporation PLC is a company specialized in supporting and promoting startups in the biopharmaceutical industry. The company is committed to developing products and therapies that have the potential to improve and prolong people's lives. Malin Corporation is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Malin Corporation stock
On Eulerpool you can find the complete historical development of Quick Ratio (Acid Test) Malin Corporation since 2006 – with annual values, charts, and detailed analysis.
The Quick Ratio measures liquidity by comparing liquid assets to current liabilities, excluding inventory. It is a more conservative measure than the current ratio.
A 'good' varies by industry and company stage. On Eulerpool, you can compare Quick Ratio (Acid Test)'s Malin Corporation with sector peers and the industry average to assess whether it is attractive.
Access this data via the Eulerpool API
Leverage — Malin Corporation
All Key Metrics — Malin Corporation
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth